
    
      The trial is an open-label, multi-center safety trial of GEN1044. The trial consists of two
      parts: a dose escalation part (phase 1) and an expansion part (phase 2a). The expansion part
      of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been determined
      from phase 1.
    
  